Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Health Through Activity: Initial Evaluation of an In-Home Intervention for Older Adults With Cancer.

Lyons KD, Bruce ML, Hull JG, Kaufman PA, Li Z, Stearns DM, Lansigan F, Chamberlin M, Fuld A, Bartels SJ, Whipple J, Bakitas MA, Hegel MT.

Am J Occup Ther. 2019 Sep/Oct;73(5):7305205070p1-7305205070p11. doi: 10.5014/ajot.2019.035022.

PMID:
31484031
2.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.

Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Acta Haematol. 2019 Jul 17:1-11. doi: 10.1159/000500666. [Epub ahead of print]

PMID:
31315113
3.

Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).

Lansigan F, Costa CA, Zaki BI, Yen SP, Winer ES, Ryan H, Findley D, Metzler SR, Shaw L, Toaso B, MacKenzie TA, Chen Y, Beaven AW.

Clin Cancer Res. 2019 Oct 15;25(20):6073-6079. doi: 10.1158/1078-0432.CCR-18-3755. Epub 2019 Jun 26.

PMID:
31243122
4.

Adenopathy and extensive skin patch overlying a plasmacytoma with unusual histologic findings in a patient with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome and Castleman disease.

Dagrosa AT, Cowdrey MCE, LeBlanc RE, Lansigan F, Kaur P, Carter JB.

J Cutan Pathol. 2019 Oct;46(10):784-789. doi: 10.1111/cup.13514. Epub 2019 Jun 19.

PMID:
31119772
5.

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP.

Blood Adv. 2019 May 28;3(10):1568-1573. doi: 10.1182/bloodadvances.2019000180.

6.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR.

Clin Cancer Res. 2019 Jul 15;25(14):4264-4270. doi: 10.1158/1078-0432.CCR-19-0361. Epub 2019 Apr 19.

PMID:
31004001
7.

Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.

Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S.

Am J Hematol. 2019 Jun;94(6):641-649. doi: 10.1002/ajh.25463. Epub 2019 Apr 9.

PMID:
30896890
8.

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR; COMPLETE Investigators.

Cancer. 2019 May 1;125(9):1507-1517. doi: 10.1002/cncr.31861. Epub 2019 Jan 29. Erratum in: Cancer. 2019 Nov 1;125(21):3893.

PMID:
30694529
9.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK.

J Clin Oncol. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7.

PMID:
30615550
10.

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.

Lansigan F, Barak I, Pitcher B, Jung SH, Cheson BD, Czuczman M, Martin P, Hsi E, Schöder H, Smith S, Bartlett NL, Leonard JP, Blum KA.

Cancer Med. 2019 Jan;8(1):165-173. doi: 10.1002/cam4.1918. Epub 2018 Dec 21.

11.

Angiolymphoid hyperplasia with eosinophilia and Kimura disease overlap, with evidence of diffuse visceral involvement.

Marka A, Cowdrey MCE, Carter JB, Lansigan F, Yan S, LeBlanc RE.

J Cutan Pathol. 2019 Feb;46(2):138-142. doi: 10.1111/cup.13379. Epub 2018 Nov 22.

PMID:
30362278
12.

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.

Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ.

Leuk Lymphoma. 2019 Apr;60(4):940-946. doi: 10.1080/10428194.2018.1515944. Epub 2018 Oct 2.

PMID:
30277110
13.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.

Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26.

PMID:
30132965
14.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.

15.

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.

Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, Pinter-Brown LC, Montoto S, Spina M, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Gabus R, Vose JM, Advani RH; T cell Project Network.

Br J Haematol. 2018 Jun;181(6):760-769. doi: 10.1111/bjh.15258. Epub 2018 Apr 19.

16.

Intravascular Large B-Cell Lymphoma Within a Thyroid Nodule: A Diagnostic Pitfall.

Linnik Y, Nicka C, Lansigan F, Loo E, Liu X.

Int J Surg Pathol. 2018 Aug;26(5):428-431. doi: 10.1177/1066896918763282. Epub 2018 Mar 23.

PMID:
29569516
17.

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M.

Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12. No abstract available.

PMID:
29527667
18.

Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin.

Pham AK, Carter JB, Ratcliffe NR, Fuld AD, Lansigan F, Burnside NJ, Guill MA 3rd, Zug KA, Jarvis LA, LeBlanc RE.

J Cutan Pathol. 2018 Jun;45(6):458-462. doi: 10.1111/cup.13140. Epub 2018 Apr 6.

PMID:
29512830
19.

Goal Attainment and Goal Adjustment of Older Adults During Person-Directed Cancer Rehabilitation.

Lyons KD, Newman RM, Kaufman PA, Bruce ML, Stearns DM, Lansigan F, Chamberlin M, Bartels SJ, Whipple J, Hegel MT.

Am J Occup Ther. 2018 Mar/Apr;72(2):7202205110p1-7202205110p8. doi: 10.5014/ajot.2018.023648.

PMID:
29426388
20.

Epidermotropic presentation by splenic B-cell lymphoma: The importance of clinical-pathologic correlation.

Hedayat AA, Carter JB, Lansigan F, LeBlanc RE.

J Cutan Pathol. 2018 Apr;45(4):299-304. doi: 10.1111/cup.13116. Epub 2018 Feb 22.

PMID:
29377231
21.

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient Sample.

Del Prete C, Kim T, Lansigan F, Shatzel J, Friedman H.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):74-77.e1. doi: 10.1016/j.clml.2017.09.008. Epub 2017 Sep 20. Review.

PMID:
29097159
22.

C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.

Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ.

Cancer. 2017 Nov 15;123(22):4411-4418. doi: 10.1002/cncr.30895. Epub 2017 Jul 27. Erratum in: Cancer. 2018 Feb 15;124(4):867. Evans, Andrew [corrected to Evens, Andrew M].

23.

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD.

J Clin Oncol. 2017 Jul 10;35(20):2260-2267. doi: 10.1200/JCO.2017.72.2157. Epub 2017 May 5.

24.

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.

Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):193-200. doi: 10.1016/j.clml.2016.10.001. Epub 2017 Jan 10.

PMID:
28209473
25.

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Cancer. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2.

26.

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.

Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M.

Am J Hematol. 2017 Feb;92(2):161-170. doi: 10.1002/ajh.24615.

27.

Acute inflammatory skin reaction during neutrophil recovery after antileukemic therapy.

Roengvoraphoj M, Yan S, Lansigan F, Chapman MS, Danilov AV.

Cutis. 2016 Oct;98(4):E13-E15. No abstract available.

PMID:
27874889
28.

A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.

Danilov AV, Lewis LD, Lansigan F, Roudaia L, Findley DL, Jones SY, Highhouse B, Beaulieu BB, Brown JR.

Br J Haematol. 2017 Sep;178(5):820-823. doi: 10.1111/bjh.14171. Epub 2016 Jul 5. No abstract available.

29.

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP.

Br J Haematol. 2016 Mar;172(5):709-15. doi: 10.1111/bjh.13883. Epub 2015 Dec 21.

30.

Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.

Reagan JL, Sullivan MR, Winer ES, Lansigan F, Cardin MS, Castillo JJ.

Leuk Res. 2015 Aug;39(8):812-7. doi: 10.1016/j.leukres.2015.04.015. Epub 2015 May 2.

PMID:
26045177
31.

Successful implementation of a rural extracorporeal photopheresis program for the treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease in a rural hospital.

Weber LL, Dunbar NM, Meehan KR, Szczepiorkowski ZM, Lansigan F.

J Clin Apher. 2015 Dec;30(6):359-63. doi: 10.1002/jca.21382. Epub 2015 Feb 17.

PMID:
25691106
32.

Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.

Sullivan MR, Danilov AV, Lansigan F, Dunbar NM.

J Clin Apher. 2015 Oct;30(5):308-10. doi: 10.1002/jca.21371. Epub 2014 Nov 21.

PMID:
25413611
33.

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.

Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM.

Ann Oncol. 2014 Nov;25(11):2211-7. doi: 10.1093/annonc/mdu443. Epub 2014 Sep 5.

34.

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS.

Blood. 2014 Oct 9;124(15):2354-61. doi: 10.1182/blood-2014-05-578963. Epub 2014 Aug 26.

PMID:
25161267
35.

Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.

Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F.

Br J Haematol. 2014 Oct;167(1):141-4. doi: 10.1111/bjh.12944. Epub 2014 May 29. No abstract available.

PMID:
24888971
36.

FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma.

Danilova OV, Dumont LJ, Levy NB, Lansigan F, Kinlaw WB, Danilov AV, Kaur P.

J Hematop. 2013 Mar;6(1):11-18.

37.

CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases.

Mody K, Wallace JS, Stearns DM, Bowers G, Lacy SR, Levy NB, Zug KA, Lansigan F.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):319-23. doi: 10.1016/j.clml.2012.12.008. Epub 2013 Jan 10. No abstract available.

PMID:
23313068
38.

Acquired angioedema and marginal zone lymphoma.

Lam DH, Levy NB, Nickerson JM, Gruenberg DA, Lansigan F.

J Clin Oncol. 2012 Jun 1;30(16):e151-3. doi: 10.1200/JCO.2011.38.9957. Epub 2012 Apr 16. No abstract available.

PMID:
22508826
39.

Bone marrow transplant for multiple myeloma: impact of distance from the transplant center.

Lipe BC, Lansigan F, Gui J, Meehan K.

Clin Adv Hematol Oncol. 2012 Jan;10(1):28-32.

40.
41.

Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13.

Lansigan F, Isufi I, Tagoe CE.

Rheumatology (Oxford). 2011 May;50(5):824-9. doi: 10.1093/rheumatology/keq395. Epub 2010 Dec 11. Review.

PMID:
21149242
42.

Navigating the treatment choices for mycosis fungoides.

Lansigan F.

Oncology (Williston Park). 2010 May;24(6):508, 516, 518. No abstract available.

43.

Current and emerging treatment strategies for cutaneous T-cell lymphoma.

Lansigan F, Foss FM.

Drugs. 2010 Feb 12;70(3):273-86. doi: 10.2165/11532190-000000000-00000. Review.

PMID:
20166766
44.

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.

Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC.

Phytomedicine. 2010 Mar;17(3-4):161-9. doi: 10.1016/j.phymed.2009.12.016. Epub 2010 Jan 22.

PMID:
20092990
45.

Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers.

Saif MW, Tytler E, Lansigan F, Brown DM, Husband AJ.

Expert Opin Investig Drugs. 2009 Apr;18(4):469-79. doi: 10.1517/13543780902762835 . Review.

PMID:
19278301
46.

Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.

Shaib W, Lansigan F, Cornfeld D, Syrigos K, Saif MW.

JOP. 2008 Nov 3;9(6):708-14.

47.

Cutaneous T-cell lymphoma.

Lansigan F, Choi J, Foss FM.

Hematol Oncol Clin North Am. 2008 Oct;22(5):979-96, x. doi: 10.1016/j.hoc.2008.07.014. Review.

PMID:
18954747
48.

ATM protein purified from vaccinia virus expression system: DNA binding requirements for kinase activation.

Chun HH, Cary RB, Lansigan F, Whitelegge J, Rawlings DJ, Gatti RA.

Biochem Biophys Res Commun. 2004 Sep 10;322(1):74-81.

PMID:
15313175
49.

Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells.

Gordon MS, Kato RM, Lansigan F, Thompson AA, Wall R, Rawlings DJ.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5504-9.

Supplemental Content

Loading ...
Support Center